Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: While much cancer research focuses on tumours and their microenvironment, malignancies cause widespread physiologic changes. Cancer and treatment‐related sarcopenia, measured with quantitative imaging or as a decrease in overall body mass, are indicative of poor prognosis in elderly diffuse large B‐cell lymphoma (DLBCL) patients, skeletal muscle radiodensity (SMD) may be a better prognostic marker. SMD, a measure of muscle radiation attenuation on CT imaging, is more prognostic than sarcopenia or International Prognostic Index (IPI) scores in follicular lymphoma and multiple solid organ malignancies. Low SMD appears to correlate with fat accumulation in muscle and is associated with inflammation. This study set out to examine SMD's prognostic ability in DLBCL. Methods: All DLBCL patients treated with rituximab‐containing therapy between 2004 and 2009 were compared to determine SMD's prognostic ability in this single centre, retrospective study. Pre‐treatment CT scans were used to measure SMD and muscle cross‐sectional area. Primary endpoints included progression free (PFS) and overall survival (OS) while objective response rates (ORR) were secondary. Results: Of 224 evaluable patients, 116 were identified as having low SMD. Low SMD predicted poorer 5 year PFS, 60 vs. 81% (p = 0.001) and OS, 58 vs. 86% (p < 0.0001). SMD's prognostic ability retained significance in multivariate analysis taking into consideration the Revised International Prognostic Index (R‐IPI) and sex. Although high SMD was not predictive of ORR (95.4 vs. 91.4%, p = 0.17), it was strongly associated with radiographic complete response (85 vs. 66%, p = 0.0007). Contrary to previous findings, sarcopenia did not predict for poorer OS but suggested improved OS in elderly DLBCL patients (HR 0.38, p = 0.01). Conclusions: SMD is a novel prognostic (and potentially treatment predictive) marker independent of R‐IPI in DLBCL. It presents an inexpensive yet complementary assessment to R‐IPI for prognosticating DLBCL outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238
Self-citationMourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224 · cited 1×
“This vertebral landmark is chosen based on its linear correlation to total body lean body mass.(16,17) Muscles were quantified within a range of 29”
MethodSelf-citationShen, W., Punyanitya, M., Wang, Z., Gallagher, D., St.-Onge, M.-P., Albu, J., Heymsfield, S. B., & Heshka, S. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00744.2004 · Cited by 1,692 · cited 1×
“This vertebral landmark is chosen based on its linear correlation to total body lean body mass.(16,17) Muscles were quantified within a range of 29”
MethodSehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., et al. (2007) · Blood · doi:10.1182/blood-2006-08-038257 · Cited by 1,473
Goodpaster, B. H., Kelley, D. E., Thaete, F. L., He, J., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.104 · Cited by 947
Goodpaster, B. H., Chomentowski, P., Ward, B. K., Rossi, A., Glynn, N. W., Delmonico, M. J., Kritchevsky, S. B., Pahor, M., & Newman, A. B. (2008) · Journal of Applied Physiology · doi:10.1152/japplphysiol.90425.2008 · Cited by 446 · cited 1×
“Although early thinking suggested this phenomenon was part of normal ageing, larger studies now suggest that intermuscular fat development is more of a product of illness and/or inactivity.(21,22) The latter explanation Table 2 Univariate and multivariate Cox proportional hazards modelling by skeletal muscle density (…”
BackgroundTardif, N., Salles, J., Guillet, C., Tordjman, J., Reggio, S., Landrier, J., Giraudet, C., Patrac, V., Bertrand‐Michel, J., Migne, C., et al. (2014) · Aging Cell · doi:10.1111/acel.12263 · Cited by 186
Tuttle, L. J., Sinacore, D. R., Cade, W. T., & Mueller, M. J. (2011) · Physical Therapy · doi:10.2522/ptj.20100329 · Cited by 113
Cited by
Myosteatosis and prognosis in cancer: Systematic review and meta-analysis
Aleixo, G. F. P., Shachar, S. S., Nyrop, K. A., Muss, H. B., Malpica, L., & Williams, G. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102839 · Cited by 345
Bozzetti, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx271 · Cited by 323
Implications of low muscle mass across the continuum of care: a narrative review
Prado, C. M., Purcell, S. A., Alish, C., Pereira, S. L., Deutz, N. E., Heyland, D. K., Goodpaster, B. H., Tappenden, K. A., & Heymsfield, S. B. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1511918 · Cited by 286
“Some studies reported no association of muscle mass or attenuation and the following outcomes: time to disease progression [135], toxicity to chemotherapy [135] and objective response to therapy [117].”
BackgroundDevelopment of selective androgen receptor modulators (SARMs)
Narayanan, R., Coss, C. C., & Dalton, J. T. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.06.013 · Cited by 251
“Studies have also demonstrated that muscle mass directly co rrelates with survival in cancer patients (95,96).”
Skeletal muscle wasting in chronic heart failure
Suzuki, T., Palus, S., & Springer, J. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12387 · Cited by 134
Metadata
- Authors
- Chu, M. P., Lieffers, J., Ghosh, S., Belch, A., Chua, N. S., Fontaine, A., Sangha, R., Turner, R. A., Baracos, V. E., & Sawyer, M. B.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2016-11-21
- Volume
- 8
- Issue
- 2
- Pages
- 298-304
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2554824743
- Cited by
- 85
- References
- 8
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy. https://app.cochat.ai/papers/10.1002/jcsm.12161
- The paper
- Chu, M. P., Lieffers, J., Ghosh, S., Belch, A., Chua, N. S., Fontaine, A., Sangha, R., Turner, R. A., Baracos, V. E., & Sawyer, M. B. (2017). Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.